Evidence map›Paper›PMID 33313323›Full record

ArticleBioMed research international2020

Mechanism of Action of Bu-Fei-Yi-Shen Formula in Treating Chronic Obstructive Pulmonary Disease Based on Network Pharmacology Analysis and Molecular Docking Validation.

Longchuan Wu, Yu Chen, Jiao Yi, Yi Zhuang, Lei Cui, Chunhui Ye

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Longchuan WuDepartment of Respiratory Medicine, Huai'an Hospital of Traditional Chinese Medicine, Huai'an, 223001, China.
Yu ChenDepartment of Respiratory Medicine, Huai'an Hospital of Traditional Chinese Medicine, Huai'an, 223001, China.
Jiao YiDepartment of Respiratory Medicine, Huai'an Hospital of Traditional Chinese Medicine, Huai'an, 223001, China.
Yi ZhuangDepartment of Respiratory Medicine, Huai'an Hospital of Traditional Chinese Medicine, Huai'an, 223001, China.
Lei CuiDepartment of Respiratory Medicine, Huai'an Hospital of Traditional Chinese Medicine, Huai'an, 223001, China.
Chunhui YeDepartment of Respiratory Medicine, Huai'an Hospital of Traditional Chinese Medicine, Huai'an, 223001, China.ORCID https://orcid.org/0000-0003-0642-4288
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the mechanism of action of Bu-Fei-Yi-Shen formula (BFYSF) in treating chronic obstructive pulmonary disease (COPD) based on network pharmacology analysis and molecular docking validation.

methodsFirst of all, the pharmacologically active ingredients and corresponding targets in BFYSF were mined by the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, the analysis platform, and literature review. Subsequently, the COPD-related targets (including the pathogenic targets and known therapeutic targets) were identified through the TTD, CTD, DisGeNet, and GeneCards databases. Thereafter, Cytoscape was employed to construct the candidate component-target network of BFYSF in the treatment of COPD. Moreover, the cytoHubba plug-in was utilized to calculate the topological parameters of nodes in the network; then, the core components and core targets of BFYSF in the treatment of COPD were extracted according to the degree value (greater than or equal to the median degree values for all nodes in the network) to construct the core network. Further, the Autodock vina software was adopted for molecular docking study on the core active ingredients and core targets, so as to verify the above-mentioned network pharmacology analysis results. Finally, the Omicshare database was applied in enrichment analysis of the biological functions of core targets and the involved signaling pathways.

resultsIn the core component-target network of BFYSF in treating COPD, there were 30 active ingredients and 37 core targets. Enrichment analysis suggested that these 37 core targets were mainly involved in the regulation of biological functions, such as response to biological and chemical stimuli, multiple cellular life processes, immunity, and metabolism. Besides, multiple pathways, including IL-17, Toll-like receptor (TLR), TNF, and HIF-1, played certain roles in the effect of BFYSF on treating COPD.

conclusionBFYSF can treat COPD through the multicomponent, multitarget, and multipathway synergistic network, which provides basic data for intensively exploring the mechanism of action of BFYSF in treating COPD.

Indexed as

Drugs, Chinese HerbalHumansHypoxia-Inducible Factor 1, alpha SubunitInterleukin-17Medicine, Chinese TraditionalMolecular Docking SimulationProtein Interaction MapsPulmonary Disease, Chronic ObstructiveSignal TransductionSoftwareToll-Like ReceptorsTumor Necrosis Factor-alphaBu-Fei-Yi-ShenDrugs, Chinese HerbalHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitIL17A protein, humanInterleukin-17Toll-Like ReceptorsTumor Necrosis Factor-alpha

Identifiers

PMID33313323
PMCPMC7718855
OpenAlexW3106960755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.